Cell Signaling Technology

Cell Signaling Technology, Inc. (CST) is a privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals.

Cell Signaling Technology, Inc.
TypePrivately held company
IndustryLife Science, Manufacturing
Founded1999
FounderMichael Comb
HeadquartersDanvers, Massachusetts
Key people
Michael Comb, President and CEO, Roberto Polakiewicz, CSO, Matthew Curran, CFO, Paul Aldridge, CDO, John Letcher, SVP HR, Benjamin Comb, SVP Corporate Strategy, Simona Levi, General Counsel, Corporate Secretary, Craig Thompson, VP Global Operations
ProductsAntibodies, ELISA Kits, ChIP Kits, Proteomics kits
Number of employees
450 — 500
SubsidiariesCell Signaling Technology Japan, K.K.
Cell Signaling Technology (China) Limited
Cell Signaling Technology Europe, B.V.
Websitewww.cellsignal.com

History

Cell Signaling Technology was founded in 1999 by scientists in the Cell Signaling group at New England Biolabs (NEB).[1]

Originally housed in the Cummings Center (Beverly, Massachusetts), CST moved to its current United States headquarters located at the former King’s Grant Inn (Danvers, Massachusetts) in late 2005.[1][2] Following extensive renovation,[3] the U.S. Green Building Council has certified the current headquarters as a LEED (Leadership in Energy and Environmental Design) certified facility in 2007.[4] In 2008 and 2009, CST expanded its overseas operations, establishing subsidiary offices in the People’s Republic of China, Japan, and the Netherlands.[5][6]

In 2013, CST moved its production group into an ISO9001 certified facility in Beverly, Massachusetts.

Cell Signaling Technology was named as one of the “Top 100 Places to Work” in a 2009-2013 survey published by the Boston Globe.[7]

Research

In addition to product development and production, CST is also involved in the development of new technologies for signaling analysis as well as mechanistic cell biology research, particularly in the field of cancer research.

CST curates and maintains PhosphoSitePlus, a web-based bioinformatics resource that details post-translational modifications (PTMs) in human, mouse and rat proteins. The types of PTMs curated include phosphorylation, acetylation, methylation, ubiquitylation, glycosylation, etc. This freely accessible, online resource is funded in part through grant support from the NIH, and most recently through the NIH BD2K initiative.[8][9]

References
  1. A lab with a view: New research space reflects company's open, research-driven philosophy
  2. "King's Grant Inn goes from hotel to biotech HQ". Archived from the original on 2011-10-03. Retrieved 2009-05-27.
  3. "NEW Room At The Inn". esmagazine.com. August 1, 2006.
  4. "Public buildings take the 'LEED' in New England". Archived from the original on 2008-12-27. Retrieved 2009-05-27.
  5. "Cell Signaling Technology opens unit in Japan". Archived from the original on 2011-10-03. Retrieved 2009-05-27.
  6. Cell Signaling Technology buys Dutch distributor
  7. Globe Top 100 Places to Work
  8. Hornbeck, Peter V.; Zhang, Bin; Murray, Beth; Kornhauser, Jon M.; Latham, Vaughan; Skrzypek, Elzbieta (2015). "PhosphoSitePlus, 2014: mutations, PTMs and recalibrations". Nucleic Acids Res. 43 (1): D512-20. doi:10.1093/nar/gku1267. PMC 4383998. PMID 25514926.
  9. "Cell Signaling Technology Announces the Availability of PhosphoScan® Profiling Technology and PhosphoSite® Knowledgebase to Academic Researchers" (Press release). Cell Signaling Technology. October 31, 2007. Retrieved October 24, 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.